Today: 8 February 2026
Subscribe

United States Antimony Corporation (UAMY) Stock: Today’s Move, Latest Contracts, Analyst Forecasts, and What Investors Are Watching on Dec. 24, 2025

United States Antimony Corporation (UAMY) Stock: Today’s Move, Latest Contracts, Analyst Forecasts, and What Investors Are Watching on Dec. 24, 2025

UAMY shares jumped 7.87% on Dec. 23, 2025, closing at $6.03 after trading in a wide range on heavy volume. Pre-market quotes on Dec. 24 showed the stock near $6.13. The company remains in focus as antimony draws attention as a critical mineral for defense and supply chains. UAMY’s recent contract wins and expansion plans have fueled volatility.
24 December 2025
·
AiRWA Inc (YYAI) Stock News, Forecasts and Analysis for Dec. 24, 2025: New 10‑Q, $15.69M Offering, and Why the Tape Is So Volatile

AiRWA Inc (YYAI) Stock News, Forecasts and Analysis for Dec. 24, 2025: New 10‑Q, $15.69M Offering, and Why the Tape Is So Volatile

AiRWA Inc. (NASDAQ: YYAI) announced a $15.69 million registered direct offering at $1.02 per share, matching the Dec. 18 close. Shares traded around $1.01 pre-market Dec. 24 after closing at $0.98 the prior session. The company, formerly Connexa Sports, recently rebranded and focuses on AI software for dating and Web3 tokenization. Proceeds target a joint venture and possible acquisitions.
24 December 2025
Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom (AVGO) Stock News Today, Forecasts and Analysis for Dec. 24, 2025: AI Margins, Tariffs, Insider Moves and Valuation

Broadcom shares traded near $350 on Dec. 24 amid thin holiday liquidity, following a volatile December driven by strong AI demand and margin concerns. The company projected Q1 revenue of $19.1 billion but warned of a 100 basis point gross margin drop due to lower-margin AI products. Broadcom reported a $73 billion backlog, mostly from five customers. U.S. delayed new China chip tariffs until 2027.
24 December 2025
··
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.
24 December 2025
··
Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute shares remain under pressure after the company’s December 11, 2025, announcement that its pivotal sunRIZE Phase 3 trial for ersodetug in congenital hyperinsulinism failed to meet primary and key secondary endpoints. The stock trades near $2.42, well below pre-trial levels, following analyst downgrades and investor-law-firm probes. Two serious hypersensitivity reactions were reported in the trial.
24 December 2025
··
Dollarama Stock (TSX: DOL) Near Fresh Highs on Dec. 24, 2025: Earnings Momentum, Global Expansion, and a Valuation Test

Dollarama Stock (TSX: DOL) Near Fresh Highs on Dec. 24, 2025: Earnings Momentum, Global Expansion, and a Valuation Test

Dollarama shares closed near C$204.69 on December 24, 2025, as the S&P/TSX approached record highs in a shortened holiday session. The stock hit fresh highs after reporting Q3 sales up 22.2% to $1.91 billion and net earnings up 16.6% to $321.7 million. Investors are debating whether its premium valuation is justified as the company expands beyond its core market.
24 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings Limited (RGC) Stock: News, Forecasts, and Fresh Analysis for Dec. 24, 2025

Regencell Bioscience Holdings (RGC) surged 14% to $25.25 on Dec. 24, 2025, despite remaining a pre-revenue company. The move followed a ValueWalk article highlighting RGC’s 17,000% gain in 2025, driven by low float, momentum trading, and a recent 38-for-1 stock split. Intraday prices ranged from $22.00 to $26.33. RGC’s market cap neared $11 billion.
24 December 2025
··
Stock Market Today: U.S. Futures Dip on Christmas Eve as S&P 500 Holds Record High and GDP Surprise Trims Rate‑Cut Bets

Stock Market Today: U.S. Futures Dip on Christmas Eve as S&P 500 Holds Record High and GDP Surprise Trims Rate‑Cut Bets

The S&P 500 closed at a record 6,909.79 Tuesday, while U.S. stock futures edged lower early Wednesday ahead of a holiday-shortened session. A strong third-quarter GDP reading at 4.3% and persistent inflation are clouding the outlook for Federal Reserve rate cuts in 2026. The NYSE will close at 1 p.m. ET, with U.S. markets shut Thursday for Christmas. Key government data releases were delayed by a federal shutdown.
24 December 2025
Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth (CGC) Stock on Dec. 24, 2025: Schedule III Executive Order, MTL Cannabis Deal, and the Latest Forecasts

Canopy Growth shares closed at $1.40 on Dec. 23, up 6.06%, after heavy trading and sharp swings throughout December. The volatility followed a Dec. 18 White House executive order directing marijuana rescheduling from Schedule I to III. Trading volume spiked to over 216 million shares on Dec. 18, with implied volatility near 143%. U.S. exchanges operated a shortened session on Dec. 24.
24 December 2025
····
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question

Indaptus Therapeutics announced a $6 million preferred-stock financing with investor David Lazar, who will become chairman and co-CEO. The deal could add up to 111 million common shares if converted, pending shareholder approval. Shares jumped over 60% after hours on December 23, 2025, following the news, after closing at $1.95 in regular trading. Two directors resigned as part of the boardroom changes.
24 December 2025
··
Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next

Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next

Churchill Capital Corp X (NASDAQ: CCCX) surged nearly 10% to $17.27 on Dec. 23, 2025, and traded above $18 pre-market after Infleqtion’s chief scientist won the John Stewart Bell Prize. The rally is linked to renewed momentum around CCCX’s planned merger with Infleqtion, a quantum technology firm. CCCX remains a SPAC, with trading driven by sentiment and headlines.
24 December 2025
···
Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands (TLRY) Stock News Today: Cannabis Rescheduling, Earnings Date, Reverse Split, and Analyst Forecasts (Dec. 24, 2025)

Tilray Brands shares traded near $10.53 on December 24, 2025, following sharp gains in the second half of the year. President Donald Trump signed an executive order on December 18 to begin the process of reclassifying marijuana from Schedule I to Schedule III. The move sparked volatility across cannabis stocks, with prices swinging as investors weighed the potential impact. The order does not legalize cannabis but directs federal agencies to review its status.
24 December 2025
··
Sable Offshore Corp (SOC) Stock News Today: PHMSA Clears Las Flores Pipeline Restart — Latest Price, Forecasts, and What Comes Next (Dec. 24, 2025)

Sable Offshore Corp (SOC) Stock News Today: PHMSA Clears Las Flores Pipeline Restart — Latest Price, Forecasts, and What Comes Next (Dec. 24, 2025)

The U.S. Pipeline and Hazardous Materials Safety Administration approved Sable Offshore Corp.’s plan to restart the Las Flores Pipeline System in California, according to a December 22 letter disclosed in an SEC filing. SOC shares surged 36% to $10.36 on December 23 and held those gains in early trading December 24. The pipelines, formerly Plains Line 901 and 903, have been at the center of a years-long dispute.
24 December 2025
··
Northann Corp Stock (NCL) Slumps After “News Pending” Halt as Dilution, Reverse Split Vote and NYSE Compliance Deadlines Loom

Northann Corp Stock (NCL) Slumps After “News Pending” Halt as Dilution, Reverse Split Vote and NYSE Compliance Deadlines Loom

Northann Corp. (NCL) shares fell 33% to $0.17 on December 23 before a NYSE American “news pending” trading halt, then rebounded in pre-market trading. The company disclosed two new advisory agreements to be paid in stock, totaling 3.3 million shares, pending exchange approval. Investors remain focused on dilution risk and listing compliance.
24 December 2025
·
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Sanofi announced a deal to acquire Dynavax Technologies for $2.2 billion in cash, offering $15.50 per share—a 39% premium to Dynavax’s prior close. DVAX stock jumped about 37% premarket to near the offer price. Dynavax’s board approved the transaction. Closing is expected in Q1 2026, pending regulatory and shareholder approvals.
24 December 2025
···
BP Stock Jumps on $6 Billion Castrol Stake Sale: What It Means for BP Shares, Debt, Dividends, and 2026 Outlook (Dec. 24, 2025)

BP Stock Jumps on $6 Billion Castrol Stake Sale: What It Means for BP Shares, Debt, Dividends, and 2026 Outlook (Dec. 24, 2025)

London/New York — December 24, 2025 — BP p.l.c. (NYSE: BP; LSE: BP.) is back in the spotlight on Christmas Eve after agreeing to sell a controlling 65% stake in its Castrol lubricants business to U.S. investment firm Stonepeak, a deal BP says values Castrol at $10.1 billion and will deliver roughly $6 billion of net proceeds to the oil major. The market’s initial reaction was positive-but-measured: BP shares rose more than 1% shortly after the announcement before trading turned choppy in thin, holiday-shortened conditions. Reuters+1 For investors, this is one of those corporate moves that reads like a clean
24 December 2025
···
1 … 774 775 776 777 778 … 1,641

Stock Market Today

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop